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Abstract 
Background: Remote measurement technologies (RMTs) can be used to collect data on 
a variety of bio-behavioural variables, which may benefit the care of people with central 
nervous system disorders. While various studies have explored their potential, prior work 
has highlighted a knowledge gap concerning healthcare professional’s perception of the 
value of RMTs in clinical practice. 
Objective: To understand the perspectives of healthcare professionals on the 
implementation of RMT in healthcare practice for the care of people with depression, 
epilepsy or multiple sclerosis.  
Methods: Semi-structured interviews were conducted with 26 multidisciplinary primary 
and secondary care healthcare professionals managing people with epilepsy, depression 
or multiple sclerosis. Interviews were transcribed verbatim and analysed using thematic 
analysis. 
Results: Eight main themes emerged from the analysis. These were: potential clinical 
value of RMT data, when to use RMT in care pathways, healthcare staff roles who may 
use RMT data, presentation and accessibility of data, obstacles to successful 
implementation of RMT, limits to the role of RMT, empowering patients, and 
considerations around alert-based systems.  
Conclusions: RMTs could add value to the system of care for individual patients with 
central nervous system disorders through providing clinicians with graphic summaries of 
data in the patient record. Barriers of both technical and human nature should be 
considered when implementing these technologies, as should the limits to the benefits 
they can offer. 
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Introduction 
In a healthcare context, remote measurement technologies (RMTs) can be used by 
healthcare professionals (HCPs) and clinical teams to collect data on a patient’s health or 
behaviour, to inform clinical decision-making. The benefits of RMTs have been explored 
for treatment/management of patients with cardiac conditions [1-3], early stage 
dementia [4], neurological disease [5] and attention deficit hyperactivity disorder 
(ADHD) [6] as well as in behaviour change [7] and monitoring for indicators of sepsis [8] 
among others.  
The European Union H2020 RADAR-CNS project [9] explores the use of RMT in the care 
of people with epilepsy, depression or multiple sclerosis. These conditions were chosen 
for this project as exemplars of central nervous system disorders which are under-
researched in relation to RMT. As part of this project, RADAR-Base, a cloud-based 
platform, is being developed to explore the potential to receive data from patients’ RMT 
and to provide this data to HCPs with a view to informing clinical decision-making [10]. 
The present study is part of this project, aiming to scope and understand the clinical 
utility of RMT in the care of patients with epilepsy, depression and multiple-sclerosis.  
Previous literature has demonstrated the benefits of implementing RMTs in healthcare 
practice. A 2013 literature review of uses of RMT in cardiology identified a number of 
studies evidencing reduced hospital visits in terms of both emergency and routine 
appointments, as well as higher survival rates, in patients who were monitored using 
RMT [11]. Benefits were also found in patient relations with the care team, quality of life, 
and compliance with treatments. No quality appraisal was conducted in this narrative 
review, however.  
Some work has challenged these findings, suggesting little or no evidence for an effect of 
RMT on key outcomes [12, 13]. Other work has highlighted a number of barriers to 
implementing RMTs in healthcare practice. Erdmier et al. [14] describe a lack of 
regulatory control over wearables, and also a number of barriers to progress in 
implementation, including technical capability, erratic user (patient) behaviour and a lack 
of transparency from manufacturers. A patient and HCP-led priority setting exercise in 
the field of digital mental health highlighted the need to explore the impact of removing 
face-to-face human interaction in care pathways for mental health conditions, and also 
raised issues of safety, effectiveness, evaluation and inequalities [15]. These issues 
apply equally to the implementation of RMTs.  
Authors of prior work in the area of RMTs highlight a need for research to investigate the 
value to HCPs of implementing RMTs [13]. Davis et al [16] conducted a systematic 
review of healthcare staff views of utilising RMT in clinical practice and included 15 
relevant studies. They concluded that “there is a critical need to engage end-users in the 
development and implementation of RMT” and highlighted that the evidence base in this 
area is small. This paper seeks to address these points by exploring HCP perspectives on 
the implementation of RMTs in three central nervous system disorders.  
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Methods 
Aim 
The study aimed to understand the perspectives of HCPs on the implementation of RMT 
in healthcare practice for the care of people with depression, epilepsy or multiple 
sclerosis (MS).  
Recruitment 
We purposively recruited a sample of 26 HCPs, with the intention of covering multiple 
clinical roles (with representation from medical, nursing and allied health professionals). 
Participants were all working in the National Health Service (NHS) in England in the care 
of people with epilepsy, depression, or multiple sclerosis, or a combination of these 
conditions. Participants were contacted through the professional networks of research 
team members. 
Procedure 
A semi-structured interview approach was deployed, with interviews lasting from 16 to 
56 minutes (mean 30 minutes). An interview schedule was used to guide questioning, 
with ad hoc follow-up questions used to further explore salient points. Participants gave 
informed consent and were incentivised with a £15 charity donation. 
Twenty three interviews were conducted one to one, while one interview was conducted 
with three participants together. Thirteen of the interviews were conducted by phone, 
while eleven were conducted in person. All interviews were recorded start to finish using 
a voice recorder. The study was approved by the University of Nottingham School of 
Medicine research ethics committee (ref 277-1802).  
Analysis 
Interviews were transcribed verbatim and analysed using thematic analysis [17]. Data 
were coded and themed (by JA) using Nvivo 12 (QSR International). Initial codes and 
themes were discussed within the research team and were iteratively renamed and 
reformed throughout the analysis process. No new themes emerged when the last 
interview was coded and so it is considered that the sample reached data saturation. 
 
Results 
Participants 
Participants were HCPs (medical doctors, nurses, clinical psychologists, physiotherapist 
and dietitian) from 13 NHS trusts (healthcare organisations) within England. Eight out of 
26 participants (31%) were female. Six specialised in the care of people with depression, 
12 in epilepsy, six in MS, and two were general practitioners working across all three 
conditions. Participants included both primary and secondary care clinicians. Thirteen of 
the 26 interviewees had used RMT with their patients, and 14 of 26 said their patients 
had brought data to appointments. Healthcare roles of the participants are presented in 
Table 1, along with their specialism and gender.  
 
Clinical specialism Depression 
(n=6) 
Epilepsy 
(n=12) 
MS 
(n=6) 
Generalist 
(n=2) 
TOTAL 
(n=26) 
Gender: n female (%) 1 (16.7) 4 (33.3) 2 (33.3) 1 (50) 8 (30.8) 
Job role: 
        Psychiatrist 
 
4 
 
- 
 
- 
 
- 
 
4 
4 
 
        Psychologist 
        Neurologist 
        Dietician 
        Specialist nurse 
        Physiotherapist 
        General practitioner 
1 
- 
- 
1 
- 
- 
- 
6 
1 
4 
- 
1 
2 
3 
- 
- 
1 
- 
- 
- 
- 
- 
- 
2 
3 
9 
1 
5 
1 
3 
Table 1. Job roles, genders and specialisms of interview participants. 
 
Thematic analysis 
Our analysis generated eight main themes, each of which also featured a number of 
subthemes.  
Theme 1: Potential clinical value of remote measurement data 
The interviews explored the types of physiological, psychosocial and lifestyle variables 
that could be targets for measurement using RMTs. HCPs described uses for certain 
variables they considered to be potentially useful in the care of people with one of the 
three conditions. Variables considered by participants to hold potential are summarised 
in table 2.  
Condition Variable 
Epilepsy Activity, anxiety, cognition, diet/food 
intake1, heart rate2, mood, quality of life, 
seizures (or proxies thereof), sleep. 
Depression Activity, anxiety, diet/food intake, mood, 
relapse signatures, sleep, weight. 
Multiple Sclerosis Activity/mobility, anxiety, cognition, 
fatigue, mood, pain, quality of life, visual 
acuity. 
Notes: 
1) Opposing views on the value of measuring diet were offered by different participants. 
2) It was noted that heart rate would be worth measuring in epilepsy only if proven to be a proxy measure of 
seizures. 
Table 2. Target variables considered potentially useful to measure using RMT. 
Epilepsy: Participants stated that it would be useful to collect data from RMTs that could 
indicate the occurrence of a seizure or number of seizures, especially in those who have 
many. However participants thought that current approaches to seizure detection (e.g. 
Empatica, Embrace) were limited by lack of sensitivity to detect the full range of seizure 
types: 
“The limitations of this particular device is that it is designed for detecting 
repetitive movements which is of use for tonic clonic seizures, however, there are 
different types of seizures which definitely don’t all involve movement but are still 
epileptic so they wouldn’t be able to detect that [..] It would be ideal to have 
something where all types of seizures would be recorded.” (P02) 
Several types of RMT data were mentioned by participants as possible proxy measures of 
seizures. These were: skin conductance, heart rate, accelerometry, pressure sensor 
readings, and electroencephalography (EEG).  There were differing views on the 
usefulness of measuring heart rate and bed pressure as proxy measures for seizures 
given the possibility of false positive signals (i.e. lack of specificity).  
Video and audio might be utilised remotely to assist with diagnosis and seizure 
identification, particularly through measurement of the sound and duration of a seizure. 
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“I will sometimes tell people who struggle to video their loved one in a seizure for 
whatever reason, just to start the video going, put the phone down, and then it 
will both record the sound, and the duration of the seizure, which are probably 
the two most useful things we need, outside of seeing one.” (P09) 
Depression: Activity data, including movement and GPS (global positioning system), 
was thought useful in detecting whether a patient was “leaving the house” (P21) or 
“getting out and about” (P06), which in turn could be considered a potential “proxy 
marker of depression severity” (P16). This was also thought to have potential to indicate 
a patient’s global level of functioning. RMT data was also thought to offer a level of 
objectivity in the measurement of depression which was otherwise lacking. Prospective 
mood monitoring using an electronic diary, and measurement of sleep using wearables, 
were also mentioned as potentially helpful in managing depression, where current 
systems such as Fitbits and mood diary apps could not collate this information together 
automatically. 
MS: Participants saw potential in the use of RMT to measure fatigue, via a self-report 
app, and also cognition given its association to relapse. However, some considered it 
difficult to pick one particular aspect of MS to measure using RMT, because the 
symptoms experienced by patients vary: 
“I don’t think you can have a particular tool that you would need to use for 
everyone. I think it is largely going to be dependent on the symptom profile.” 
(P20) 
Multiple participants mentioned visual acuity as an important indicator of relapse which 
could be measured using RMT, although they were unsure if technology would be able to 
measure it when even well trained humans struggled: 
“It would have to be really well designed to pick up those intricacies [..] 
sometimes it is really difficult even for the neurologist to say this person is having 
a relapse or they are not” (P19) 
 
Theme 2: When to use RMT in the care pathway 
Participants described different points in care pathways when data from RMTs could 
usefully inform the care of their patients. Figures 1 to 3 demonstrate where participants 
indicated it could be useful to receive data from RMTs. Clinicians indicated that they 
would like data collected via RMT to be readily accessible in their electronic patient 
record when patients attended for appointments. 
NB. It is acknowledged that not every patient’s journey along a care pathway follows the 
same trajectory. These figures are for illustrative purposes only.  
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Figure 1. Participant comments about timing of the use of RMT in the epilepsy care 
pathway, including monitoring on a yearly basis once stable to allow assessment of 
follow-up and to create data for future research. 
 
 
Figure 2. Participant comments about timing of the use of RMT in the depression care 
pathway, including monitoring during a change in treatment. 
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Figure 3. Participant comments about timing of the use of RMT in the multiple sclerosis 
care pathway, indicating the benefits of monitoring for a short period of time prior to an 
appointment. 
 
Theme 3: Healthcare staff roles who may use RMT data 
Participants discussed the healthcare staff roles that should be involved in using any 
data from RMTs. Across all three conditions, participants suggested that primary care 
was a good place for data to be managed, given the systems available. 
“Primary care is certainly quite well set up with systems in place to action on 
things based through the electronic patient record.” (P06) 
In secondary care, specialist nurses were considered to have the closest relationships 
with patients among members of the care team, and thus were suggested to be the 
team member most likely to review data from RMTs. For example, in epilepsy: 
“If it’s sort of data that is being in some way downloaded in between clinics, then 
there would certainly be a role for something like an epilepsy nurse to look at that 
data.” (P09) 
Participants considered it important that all clinical, but not administrative, members of a 
team involved in the treatment of a patient should have access to RMT data when it is 
collected. 
“The discussions we’ve had are about, is it appropriate for admin staff to review 
that or actually does it have to be a clinician from a risk perspective [..] Your 
economic arguments come in about experienced clinicians are too expensive but I 
think making the wrong triage decision is also too expensive.” (P21) 
 
Theme 4: Presentation and accessibility of RMT data 
Participants had a variety of views on the best way for data to be presented to them. 
Particular emphasis was placed on the importance of interoperability and the ability for 
any data from RMTs to be accessible within an existing electronic patient record (EPR) 
system rather than requiring the opening of another window or program. 
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“If [..] you want to have the information available to you at times other than 
when your patient is there, then it would be good if it could feed directly into your 
electronic patient record.” (P07) 
Across all three conditions, HCPs were keen to have data aggregated in a visual/ 
graphical format. Some also recalled instances where they had used devices or software 
which presented information in graphs automatically, and commented that this was 
useful for the patient as well as for the clinician. 
 “For most of them [mood-reporting apps] you can do a graph function so they 
can show you the whole three months, in a fairly small chart, which helps us to 
think about if there have been any stresses or life events that have changed their 
mood or whether there’s a pattern to the time of day, and so on.” (P07) 
Speed of access to information was also considered to be a priority. Participants spoke of 
particular situations in which the use of digital records could usefully increase efficiency 
through time-saving. 
“I certainly think if you can access the information quickly then it could be a focus 
point for the whole consultation and it could speed things up.” (P16) 
Uploading data to the EPR was considered preferable to reviewing data that patients 
brought to the clinic on their mobile phones. 
“It could be sent in and loaded up in the patients notes or some other big screen 
device otherwise you are kind of stuck with little handheld mobiles and it’s not 
really that helpful.” (P13) 
 
Theme 5: Obstacles to successful implementation of RMTs 
Participants mentioned several aspects of the use of RMTs which they considered to be 
obstacles to their successful use and adoption in practice. These fitted into two broad 
categories of ‘technical issues’ and ‘human issues’.  
The most frequently mentioned technical issue was data accuracy (“I’m not sure they’re 
accurate”, P03). However, participants indicated they would be happy to use devices 
even where these provided data which were not 100% accurate, so long as the clinician 
was aware of the margins of error that the data may contain. 
“So being as clear as possible what the potential pitfalls might be about all the 
data that we get back [..] I think as long as you know, kind of where it might go 
wrong, or how to be careful which bits to not over-interpret, then I think it’s fine” 
(P09) 
There was also concern about the interoperability of any new systems with existing ones, 
as clinicians are already required to use several different software packages to manage 
patients. 
“The main trouble currently is a lack of integration” (P01) 
Data security was also discussed as an important issue to consider, although participants 
had differing views on the level of risk that providing data remotely may entail. Some 
had concerns. 
 “Who has access to this data? Including if they have it on their phone, what if 
their phone goes missing, where does this data go? There’s a big big, data 
protection bit, there’s a big big, patient safety bit.” (P03) 
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Some advocated taking a pragmatic approach to reduce risk while continuing to use 
technology where it provided a benefit. 
“I think as long as appropriate safeguards are taken then that’s fine, and I think 
sometimes this can be a barrier, an unnecessary barrier to introducing things that 
can be helpful.” (P06) 
Human issues considered obstacles to the use of RMTs largely focused on two areas: 
patient anxiety and patient motivation. Participants discussed ways in which the use of 
RMTs may cause patients anxiety through over-focussing on their symptoms, and how 
this in turn could be problematic for a health service. 
“We have had quite a few patients coming in that have used these monitoring 
devices and say my heart rate is really fast. For them it’s another layer of 
education so it actually creates us more work.” (P03) 
However, others were less concerned, believing that RMTs would not induce anxiety in 
people who were not prone to it in the first place or that any anxiety would be 
manageable. 
“We’ve always found ways to react to that anxiety, this is just what it looks like in 
the current generation.” (P21) 
Participants suggested that patients with depression would have less motivation to 
engage with RMTs as a result of their condition.  
“A lot of our patients may, especially if they’re more severely depressed, not be 
very motivated to interact with the app” (P16) 
However, the use of RMTs to generate more objective evidence of a patient’s health 
state was considered by some to be useful in motivating engagement with their care. 
“So if you do your usual interview and you’ve got objective evidence to say, I 
think your depression is coming back or you haven’t been exercising enough or 
you have way more seizures than you think, then of course, that might help 
motivating them to do certain things.” (P22) 
 
Theme 6: Limits to the role of RMT 
Several of our participants mentioned elements of care in their specialism which, in their 
view, should not be replaced by an RMT-enabled approach. In MS, the importance of 
face to face appointments was highlighted as essential for picking up subtle signs of 
worsening condition. 
“You really need to be physically examining the patient as well as hearing their 
perspective because there's subtle deficits that you can pick up on at examination 
that people won't notice day to day [..] you can pick up things like subtle signs 
like nystagmus, or problems with the balance or things like that, that people 
often won't notice” (P01) 
In epilepsy too, HCPs reiterated the importance of seeing their patients face to face. 
“If their seizure frequency has increased you’re there thinking I probably need to 
see you, what else is going on? Have they got a cold, a water infection? Is there 
something else going on in their life? Are they not taking their tablets? 
Sometimes some of those conversations need to be had.” (P03) 
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A general practitioner mentioned the relational side of their work as important in the 
care of people with depression. 
“The relationship element of it is very important, and obviously in primary care a 
lot of what I’m thinking is around depression [..] the human to human contact 
with someone who’s struggling with mood, and the fact that you’ve got someone 
who can be empathic and rapport rather than just crunching data” (P06) 
 
Theme 7: Empowering patients 
HCPs believed that RMT may benefit patients because it might empower them to take a 
leading role in their care. Some clinicians thought that patients should lead the use of 
technology, and therefore have more control over their own care. 
“The way I see it is it’s more about the patient using the data for themselves, the 
clinician is almost the passive recipient of the data who is working with the 
patient to try and interpret it and help them develop techniques to use the data 
themselves.” (P07) 
HCPs also spoke of how patients could be given full control of their own data collected 
using RMTs, and allow that data to be shared with a chosen clinician when they deemed 
it necessary. 
“Within the patient held database, [..] presumably a sort of secure log in, and 
that is, it’s patient-controlled [..] and they could give out the ability to share.” 
(P15) 
Participants provided examples of how a patient could be empowered through the use of 
RMT, by determining when to arrange an appointment based on the outputs from the 
technology. 
“Through prospective mood monitoring you could capture periods where there 
had been a persistent lowering of mood over two weeks or more with associated 
other features or even shorter periods than that, that you’d agreed as part of a 
relapse signature. What people could do in those instances is potentially bring 
appointments forward.” (P13) 
However, in the case of depression, participants saw difficulties with patient motivation 
and thus thought it unlikely that patients would be able to take control of their own care. 
“[That] involves them taking a lot of responsibility for their own healthcare and I 
guess that may work better in some conditions, more than depression.” (P16) 
For some, it was a case of providing care on an individual basis. 
“I would tailor it to what they wanted, so you will have those who are very tech 
savvy who don’t have any time and think this will really suit me, others are very 
much I really want to see you doctor [..] the key is to listen to them and 
individualise care rather than doing tick box medicine which we sometimes do.” 
(P03) 
 
Theme 8: Alert-based systems 
There was debate across all three conditions in the interviews about the potential to use 
RMT to alert clinicians when a monitoring variable fell outside normative parameters, for 
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example if seizures increased in severity or frequency, if mood or activity were found to 
be particularly low, or if fatigue increased. The majority of participants considered such a 
system to be beneficial, so that interventions could be put in place as soon as possible. 
“It would be a system that had parameters set and triggered active alerts when 
those parameters were exceeded, I think would be the only way that I could see 
a lot of our consultant body engaging in it.” (P01) 
However, a small number thought such a system would be problematic, principally 
because alerts may create excessive demand for immediate processing, interpretation 
and/or response (for example outside of normal working hours) and there would not be 
enough healthcare staff available to respond to the alerts produced. 
“Outside of fixed appointments the question would be who would actually have 
time and headspace to actually look at what was being flagged up. You would 
need to really carefully think about the staffing in the NHS and mental health 
services.” (P13) 
HCPs also perceived there to be a risk that alerts would go unnoticed in the system 
(P03: “My worry is this data arrives and nobody looks at it for weeks, it’s sitting 
somewhere in the ether”). Several participants suggested that it would be more useful if 
the technology alerted the patient to take action through their regular treatment 
pathways, rather than putting the onus on the clinician. 
 “I would want it to prompt the patient to make contact with me.” (P14) 
Some saw a need for further research to determine the benefits of an alert-based 
system. 
“Unless you could do a good study and demonstrate that sending me alerts from 
an automated app would be helpful, then I would just want information that I 
could look back on when I next met with a patient face to face” (P14) 
 
Discussion 
Principal findings 
Eight themes emerged from the analysis of our interviews. The first theme covered the 
potential clinical value of remote measurement data. Where RMTs are currently used in 
healthcare practice, HCPs find them to be largely inaccurate, particularly in the case of 
epilepsy, though efforts to develop more effective ways of monitoring epilepsy are 
welcomed. Participants were optimistic about the future use of activity data to monitor 
symptoms of depression, and considered that using RMT to collect measures of fatigue 
and cognition in people with MS would be useful. 
In Theme 2, key points in care pathways for the three conditions were identified as times 
where RMT data could provide most value. These included monitoring a short period of 
time prior to an appointment (MS), monitoring during a change in treatment (epilepsy), 
and monitoring on a regular basis once a patient was in a stable condition, to allow 
assessment of follow-up and to create data for future research (depression, epilepsy and 
MS). 
The third theme considered staff roles in the management of RMT use by patients. 
Participants suggested all staff involved in a patient’s care should have easy access to 
data generated by RMTs via the patient record. Participants also made it clear that triage 
using data from RMTs should be conducted by qualified HCPs rather than by 
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administration staff. Primary care staff, and specialist nurses in secondary care, were 
thought to be well placed to manage incoming data from patients.  
With regard to presentation of data, in Theme 4, HCPs described ease and speed of 
access to RMT data to be important for their successful use, and emphasised the 
importance of interoperability with the patient record. Presentation of data in graphs was 
mentioned as helpful for interpretation. 
Theme 5 discussed obstacles to the successful use of RMTs, and these included both 
‘technical issues’ such as data accuracy and data security (where views differed on the 
risks involved), and ‘human issues’, such as anxiety created by monitoring (although not 
all participants agreed that this was an issue). 
In theme 6 on the limits of RMT benefit, participants emphasised that RMT would never 
completely replace face to face appointments, particularly in depression where 
relationship was considered important. 
The seventh theme concerned patient empowerment. HCPs expressed the value in giving 
patients access to their own data, enabling them to take an active role in their own care, 
for example by advancing appointments where RMT data indicated it was necessary. 
However, there was some concern about depression patients having the motivation to 
take responsibility for their own care. 
Theme 8 related to alert-based systems. Participants debated the value of such systems, 
and highlighted requirements for their successful use. Some thought alerts should be 
used to invite the patient to take action rather than alerting a clinician, due to workload 
concerns. The need for further research to determine the benefits of alert-based systems 
was also highlighted. 
 
Comparison with prior work 
While prior work exploring RMT in healthcare has principally identified benefits and 
barriers to its implementation (e.g. [11] [14]), the present study has investigated HCPs’ 
perceptions of the clinical value of implementing RMTs, helping to address a knowledge 
gap identified by Vegesna et al. [13] and Davis et al [16].  
The themes emerging in this study add to findings from prior work in this area. Our 
findings support the work of Bruno et al [18], who highlight that healthcare professionals 
may view the management of data from digital devices as a burden. Goodrich and 
colleagues, among others, have highlighted the importance of interoperability and a 
preference for data from mobile technologies to be automatically integrated into clinical 
records [19], similar to the views of our participants. Clinician concern about the need to 
respond to alert-based systems has also been raised previously [16, 20].  
Prior work has also emphasised the importance of face-to-face contact in the context of 
digital technology and mental health care [21]. A priority setting exercise for digital 
mental health [15] identified a need to explore the impact of removing such interactions 
from care pathways. Our data has shown that HCPs view face-to-face appointments as 
essential in the care of patients with these three conditions, even where RMT could 
provide them with detailed recent data on a patient’s status. Our data show too that 
HCPs imagine patients could be empowered to determine their own need for a clinical 
appointment based on data from RMT, helping to address questions around impact of 
technology on access to services which has also been identified as a research priority 
[15]. 
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Davis’ Technology Acceptance Model [22] describes perceived usefulness and perceived 
ease of use as key mediators to the successful uptake of a new technology. Our analysis 
highlights ways in which clinicians perceive RMT data could be useful (theme 1), as well 
as where there are limits or obstacles to this usefulness (themes 5 and 6). We have also 
identified how speed and ease of access to data are desirable for HCPs (theme 4), 
evidencing how perceived ease of use is applicable to this area. The analysis also raises 
the tailoring of care for patients using RMT (theme 7), where it was discussed that 
patients’ perception of RMT should be that it is both useful and easy to use in order to 
motivate continued use. 
Beyond the findings presented in previous work, our findings specify the types of RMT 
data clinicians would value in the management of epilepsy, depression and MS, as well 
as the points in patient care at which these data would be of most use and the 
healthcare roles that would be best placed to manage this data. 
 
Implications for researchers and developers 
Findings from these themes will help to inform the development of the RADAR-CNS 
approach in the application of RMT for better care for epilepsy, MS and depression. 
Researchers and companies developing monitoring technologies should ensure the 
boundaries of accuracy of any new solution are well defined, such that clinicians can 
understand the level of confidence they should place in readings from such devices. 
Since HCPs believe patients may benefit from the option to move/advance appointments 
based on their data, it would also be worthwhile for any mobile health solutions to link 
with appointment planning services, so that these can be easily accessed. In the United 
Kingdom, the NHS app is an example of such a system.  
 
Strengths and limitations 
This study has a number of strengths. We recruited a multidisciplinary group of HCPs 
working in a variety of clinical staff roles in primary and secondary care.  Therefore the 
use of RMTs was considered from multiple perspectives. The study was limited in its 
consideration of only three specific central nervous system disorders in one national 
health care system. However, the analysis has considered how insights gained from staff 
working in these three conditions might generalise, and has permitted a deeper analysis 
of the three conditions mentioned. The ratio of male to female participants was high, 
with only eight out of 26 participants being female. Epilepsy staff were over-represented 
in comparison with depression and multiple sclerosis due to the convenience sampling 
method. However, staff were represented across most roles in the care team for each of 
the three conditions represented, with the exception of MS, where an MS nurse could not 
be recruited in the time available. 
 
Future directions 
While we have focussed our consideration of the use of patient RMT data on an individual 
basis, further work could usefully explore the use of combined RMT data from groups of 
patients to assess risk or identify trends. The 2019 Topol Review highlighted the 
potential of integrating predictive analytics into diagnosis and care pathways [23], and 
data from RMTs could feed into these approaches.  
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Work should also explore the views of health service managers, commissioners and 
public health representatives to understand the value that implementation of RMTs could 
provide from a healthcare system payer and management perspective, for example in its 
potential to increase efficiencies and improve outcomes for different patient populations. 
Given participants’ views on the importance of nurses’ roles in the management of 
patients’ use of RMT, it would be useful to conduct further research to better understand 
nurses’ views on subsuming associated responsibilities into their roles. While some work 
has explored nurses’ views on their roles in use of technology in intensive care situations 
[24] and telehealth for diabetes [25], to our knowledge none has yet explored views 
specifically relating to RMT in CNS disorders. 
Further work should also be completed to understand how RMTs might best facilitate 
increased patient autonomy (as advocated in the NHS Long Term Plan [26]), and 
situations where this may be less appropriate or successful. The RADAR-MDD study is 
recruiting 600 people with major depressive disorder to use RMTs over a period two 
years, and this study may shed light in this area [27]. 
 
Conclusions 
This paper has explored the views of healthcare professionals on implementing remote 
measurement technology in the management of central nervous system disorders, 
specifically in epilepsy, MS and depression. The results have detailed: 
• target physiological variables for measurement that clinicians believe would be 
useful 
• points in care pathways at which clinicians perceive benefit to patients using 
RMTs 
• roles of healthcare staff best placed to manage incoming data 
• HCPs’ preferred presentation of data 
• obstacles to the successful implementation of RMTs 
• limits to the benefits that RMT can provide 
• ways in which patients may be empowered through use of RMTs 
• considerations around alert-based systems. 
Our findings show the importance of early engagement and co-design with healthcare 
professionals when considering user requirements and potential use cases before 
implementing RMT in clinical care pathways. HCPs believe that RMT data can add value 
to the care of patients with these three conditions, but are not sufficient for decisions 
about care to be made exclusively on the basis of these data. We have demonstrated 
that clinicians are pragmatic about the data security risks of using RMT data with 
patients. Further research is required to establish how RMT data could be used on a 
population level to benefit patients with central nervous system disorders. 
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